Planning analysis for locally advanced lung cancer: dosimetric and efficiency comparisons between intensity-modulated radiotherapy (IMRT), single-arc/partial-arc volumetric modulated arc therapy (SA/PA-VMAT)

Radiation Oncology

Youling Gong¹  Xiaojuan Zhou²  Yong Xu²  Lin Zhou²  Yongmei Liu²  Tao Li³  Xiaoqin Jiang³ 

[1] State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, PR.China;Department of Thoracic Oncology and Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, PR.China;Radiation Physics Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, PR.China

关键词: Normal tissue toxicity;    Target dose distribution;    Volumetric modulated arc therapy;    Intensity-modulated radiotherapy;    Lung cancer;   

Others  :  1223875
DOI  :  10.1186/1748-717X-6-140

 received in 2011-08-10, accepted in 2011-10-21,  发布年份 2011

【 摘 要 】

Purpose

To analyze the differences between the intensity-modulated radiotherapy (IMRT), single/partial-arc volumetric modulated arc therapy (SA/PA-VMAT) techniques in treatment planning for locally advanced lung cancer.

Materials and methods

12 patients were retrospectively studied. In each patient's case, several parameters were analyzed based on the dose-volume histograms (DVH) of the IMRT, SA/PA-VMAT plans respectively. Also, each plan was delivered to a phantom for time comparison.

Results

The SA-VMAT plans showed the superior target dose coverage, although the minimum/mean/maximum doses to the target were similar. For the total and contralateral lungs, the higher V_5/10, lower V_20/30 and mean lung dose (MLD) were observed in the SA/PA-VMAT plans (p < 0.05, respectively). The PA-VMAT technique improves the dose sparing (V₂₀, V₃₀ and MLD) of the controlateral lung more notably, comparing to those parameters of the IMRT and SA-VMAT plans respectively. The delivered monitor units (MUs) and treatment times were reduced significantly with VMAT plans, especially PA-VMAT plans (for MUs: mean 458.3 vs. 439.2 vs. 435.7 MUs, p < 0.05 and for treatment time: mean 13.7 vs. 10.6 vs. 6.4 minutes, p < 0.01).

Conclusions

The SA-VMAT technique achieves highly conformal dose distribution to the target. Comparing to the IMRT plans, the higher V_5/10, lower V_20/30 and MLD were observed in the total and contralateral lungs in the VMAT plans, especially in the PA-VMAT plans. The SA/PA-VMAT plans also reduced treatment time with more efficient dose delivering. But the clinical benefit of the VMAT technique for locally advanced lung cancer needs further investigations.

【 授权许可】

   
2011 Jiang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Otto K: Volumetric modulated arc therapy: IMRT in a single arc. Med Phys 2008, 35:310-7.
• [2]Bedford JL, Hansen VN, McNair HA, Aitken AH, Brock JE, Warrington AP, Brada M: Treatment of lung cancer using volumetric modulated arc therapy and image guidance: a case study. Acta Oncol 2008, 47:1438-43.
• [3]Scorsetti M, Navarria P, Mancosu P, Alongi F, Castiglioni S, Cavina R, Cozzi L, Fogliata A, Pentimalli S, Tozzi A, Santoro A: Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc. Radiat Oncol 2010, 5:94. BioMed Central Full Text
• [4]McGrath SD, Mathuszak MM, Yan D, Kestin LL, Martinez AA, Grills IS: Volumetric modulated arc therapy for delivery of hypofractionated stereotactic lung radiotherapy: A dosimetric and treatment efficiency analysis. Radiother Oncol 2010, 95:153-7.
• [5]Cao D, Holmes T, Afghan M, Shepard DM: Comparison of plan quality provided by intensity-modulated arc therapy and helical tomotherapy. Int J Radiat Oncol Biol Phys 2007, 69:240-50.
• [6]Holt A, van Vroegindeweij C, Mans A, Belderbos JS, Damen EM: Volumetric-modulated arc therapy for stereotactic dosy radiotherapy of lung tumors: a comparison with intensity modulated radiotherapy techniques. Int J Radiat Oncol Biol Phys 2011, in press.
• [7]Pesce GA, Clivio A, Cozzi L, Nicolini G, Richetti A, Salati E, Valli M, Vanetti E, Fogliata A: Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy. Radiat Oncol 2010, 5:54. BioMed Central Full Text
• [8]Stieler F, Wolff D, Lohr F, Steil V, Abo-Madyan Y, Lorenz F, Wenz F, Ma S: A fast radiotherapy paradigm for anal cancer with volumetric modulated arc therapy (VMAT). Radiat Oncol 2009, 4:48. BioMed Central Full Text
• [9]Verbakel WF, Cuijpers JP, Hoffmans D, Bieker M, Slotman BJ, Senan S: Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study. Int J Radiat Oncol Biol Phys 2009, 74:252-9.
• [10]Bertelsen A, Hansen CR, Johansen J, Brink C: Single arc volumetric modulated arc therapy of head and neck cancer. Radiother Oncol 2010, 95:142-8.
• [11]Guckenberger M, Richter A, Krieger T, Wilbert J, Baier K, Flentje M: Is a single arc sufficient in volumetric-modulated arc therapy (VMAT) for complex-shaped target volumes? Radiother Oncol 2009, 93:259-65.
• [12]Greene FL, Compton CC, Fritz AG, et al.: AJCC cancer staging. Atlas New York: Springer; 2006:77-88.
• [13]Gong YL, Wang SC, Zhou L, Liu YM, Xu Y, Lu Y, Bai S, Fu YC, Xu QF, Jiang QF: Dosimetric comparison using different multileaf collimeters in intensity-modulated radiotherapy for upper thoracic esophageal cancer. Radiat Oncol 2010, 5:65. BioMed Central Full Text
• [14]Yang Y, Zhang P, Happersett L, Xiong J, Yang J, Chan M, Beal K, Mageras G, Hunt M: Choreographing couch and collimator in volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2011, 80:1238-47.
• [15]Claude L, Perol D, Ginestet C, Falchero L, Arpin D, Vincent M, Martel I, Hominal S, Cordier JF, Carrie C: A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 2004, 71:175-81.
• [16]Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM: Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 2003, 67:275-83.
• [17]Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45:323-9.
• [18]Hernando ML, Marks LB, Bentel GC, Zhou SM, Hollis D, Das SK, Fan M, Munley MT, Shafman TD, Anscher MS, Lind PA: Radiation induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001, 51:650-9.
• [19]Schallenkamp JM, Miller RC, Brinkmann DH, Foote T, Garces YI: Incidence of radiation pneumonitis after thoracic irradiation: dose-volume correlates. Int J Radiat Oncol Biol Phys 2007, 67:410-6.
• [20]Wang S, Liao Z, Xie W, Liu HH, Tucker SL, Hu CS, Mohan R, Cox JD, Komaki R: Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2006, 66:1399-407.
• [21]Palma DA, Senan S, Haasbeek CJA, Verbakel WF, Vincent A, Lagerwaard F: Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimentional conformal and volumetri-modulated arc therapy technique. Int J Radiat Oncol Biol Phys 2011, 80:506-13.
• [22]Yorke ED, Jackson A, Rosenzweig KE, Braban L, Leibel SA, Ling CC: Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 2005, 63:672-82.
• [23]Ramella S, Trodella L, Claudio Mineo T, Pompeo E, Stimato G, Gaudino D, Valentini V, Cellini F, Ciresa M, Fiore M, Piermattei A, Russo P, Cesario A, D'Angelillo RM: Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy. Int J Radiat Oncol Biol Phys 2010, 76:110-5.